Botulinum toxin treatment for overactive bladder: risk of urinary retention

AM Shaban, M Drake

Research output: Contribution to journalArticle (Academic Journal)peer-review

22 Citations (Scopus)


In recent years, botulinum-A neurotoxin has increasingly been used to manage lower urinary tract symptoms, including overactive bladder and detrusor overactivity (DO), either due to neurogenic or idiopathic etiology. Techniques, doses, and preparation vary. Although many studies have reported promising results regarding efficacy, potential adverse effects, particularly urinary retention, have been less comprehensively reported. We performed a critical review of published studies evaluating botulinum treatment for overactive bladder and its reported effects on voiding function. Acute urinary retention is recognized, though rare. Chronic urinary retention is inconsistently reported; it appears to be more common in neurogenic DO, but it can occur in idiopathic DO. Increased postvoid residuals have been reported by several studies, but the clinical significance that investigators attach to the observation varies. The detrimental effect of retention on quality of life can be considerable. Accordingly, patients should be fully counseled on the risks of urinary retention and trained in intermittent catheterization before the procedure. Postvoid residual assessment should be part of follow-up and patients should be warned of possible presentations.
Translated title of the contributionBotulinum toxin treatment for overactive bladder: risk of urinary retention
Original languageEnglish
Pages (from-to)445 - 451
Number of pages7
JournalCurrent Urology Reports
Publication statusPublished - Nov 2008


Dive into the research topics of 'Botulinum toxin treatment for overactive bladder: risk of urinary retention'. Together they form a unique fingerprint.

Cite this